Related Experiment Video
Updated: May 9, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically-Based
Yuran Cao1,2, Yuming Hu3, Jing Zhang2
1School of Pharmacy, Fudan University, Shanghai, China.
None:
Inhaled formulations are the first choices for treating asthma and chronic obstructive pulmonary disease (COPD). Both local and systemic exposures need to be considered when assessing the efficacy and safety of inhaled drugs. Physiologically-based pharmacokinetic (PBPK) models were constructed and verified for budesonide and formoterol with different inhalation devices, CXG87 (test (T) formulation) and Symbicort® Turbuhaler® (reference (R) formulation). The models were then used to evaluate local exposures at different peak inspiratory flow rates (PIFRs) and dose conditions. Local exposures of CXG87 were comparable to the R formulation at PIFR 50-80 L/min at the dose of 200 μg/6 μg (budesonide/ formoterol fumarate), which was determined as the recommended dose. At this dose, CXG87 had local exposure advantages compared with the R formulation at PIFR 30-50 L/min and better local exposure stability at PIFR 30-80 L/min in the indication population. The simulation results indicated that 200 μg/6 μg can be selected as the study dose in the subsequent clinical study of CXG87 in indication patients. In addition, the clinical study could also include a lower flow rate (30-50 L/min) patient population to further evaluate the advantages of the modified formulation CXG87. This is the first study to predict CXG87 local exposure by a verified PBPK model.
More Related Videos
04:59Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
09:29An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing
Published on: May 13, 2020
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution